Field Trip Health Ltd

Developer and provider of psychedelic therapies Field Trip Health Ltd. has announced the first successful dosing of a Phase 1 clinical trial on it's proprietary psychedelic molecule. The Phase 1 trial is a double-blind, randomized, placebo-controlled study investigating the safety,...

Psychedelic therapies developer and provider Field Trip Health Ltd. (TSX: FTRP) (NASDAQ: FTRP) reported fiscal fourth quarter and full year 2022 results for the period ended March 31, 2022 and completed a strategic review resulting in the intention to separate the Field Trip Discovery and Field...

Get into psychedelics now. That's according to Michael "Zappy" Zapolin, a former Bear Stearns VP turned psychedelics advocate and filmmaker. Zappy's call to invest comes as psychedelics make a continued push towards credibility on the medical, legal and business...

Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol...